Anny Camelo Castillo

Dr. Anny Camelo Castillo

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2019 in Science Immunology
Verified
Journal Article
Closed access
PDF file
EDEmma E. Dutton
Emma E. Dutton
DGDominika W. Gajdasik
Dominika W. Gajdasik
CWClaire Willis
Claire Willis
RFRemi Fiancette
Remi Fiancette
EBEmma L. Bishop
Emma L. Bishop
DWDavid R. Withers
David R. Withers
Tissue residency is considered a defining feature of the innate lymphoid cell (ILC) populations located within mucosal and adipose tissues. ILCs are also present within all lymphoid tissues, but whether ILCs migrate between lymphoid and nonlymphoid sites and in what context is poorly understood. To determine whether migratory ILCs exist within peripheral lymph nodes (LNs), we labeled all cells within the brachial LN (bLN) of transgenic mice expressing a photoconvertible fluorescent protein by direct exposure to light. Tracking of cellular changes in the labeled LN revealed the gradual migration of new ILCs into the tissue, balanced by egress of ILCs dependent on sphingosine-1-phosphate receptors. Most of the migratory ILCs were ILC1s, entering LNs directly from the circulation in a CD62L- and CCR7-dependent manner and thus behaving like conventional natural killer (cNK) cells. Upon egress, both ILC1s and cNK cells were found to recirculate through peripheral LNs. A distinct population of migratory ILC2s were detected in the LN, but most of the ILC3s were tissue resident. Functionally, both migratory and resident ILC1s within LNs were able to rapidly produce IFN-γ to support the generation of robust TH1 T cell responses after immunization. Thus, migratory and resident ILC populations exist within peripheral LNs, with ILC1s, akin to cNK cells, able to traffic into these tissues where they can contribute to the initiation of adaptive immunity.

11 February 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ACAnny Camelo Castillo
Anny Camelo Castillo
JRJosé Miguel Rivera-Caravaca
José Miguel Rivera-Caravaca
Esteban Orenes-PiñeroEsteban Orenes-Piñero
Esteban Orenes-Piñero
Inmaculada Ramírez-MacíasInmaculada Ramírez-Macías
Inmaculada Ramírez-Macías
VRVanessa Roldán
Vanessa Roldán
FMFrancisco Marin
Francisco Marin
The efficacy and safety of vitamin K antagonists (VKAs) as oral anticoagulants (OACs) depend on the quality of anticoagulation control, as reflected by the mean time in therapeutic range (TTR). Several factors may be involved in poor TTR such as comorbidities, high inter-individual variability, interacting drugs, and non-adherence. Recent studies suggest that gut microbiota (GM) plays an important role in the pathogenesis of cardiovascular diseases, but the effect of the GM on anticoagulation control with VKAs is unknown. In the present review article, we propose different mechanisms by which the GM could have an impact on the quality of anticoagulation control in patients taking VKA therapy. We suggest that the potential effects of GM may be mediated first, by an indirect effect of metabolites produced by GM in the availability of VKAs drugs; second, by an effect of vitamin K-producing bacteria; and finally, by the structural modification of the molecules of VKAs. Future research will help confirm these hypotheses and may suggest profiles of bacterial signatures or microbial metabolites, to be used as biomarkers to predict the quality of anticoagulation. This could lead to the design of intervention strategies modulating gut microbiota, for example, by using probiotics.

3 November 2021 in International Microbiology
Verified
Journal Article
Closed access
PDF file
HLHiram D. López-Santacruz
Hiram D. López-Santacruz
ALArantxa López-López
Arantxa López-López
ARAinhoa Revilla-Guarinos
Ainhoa Revilla-Guarinos
ACAnny Camelo Castillo
Anny Camelo Castillo
VEVicente Esparza-Villalpando
Vicente Esparza-Villalpando
SRSaray aranda romo
Saray aranda romo

Verified
Journal Article
Open access
PDF file
JRJosé Miguel Rivera-Caravaca
José Miguel Rivera-Caravaca
ACAnny Camelo Castillo
Anny Camelo Castillo
Inmaculada Ramírez-MacíasInmaculada Ramírez-Macías
Inmaculada Ramírez-Macías
PPPablo Gil Pérez
Pablo Gil Pérez
CLCecilia López-García
Cecilia López-García
FMFrancisco Marin
Francisco Marin
Peripheral artery disease (PAD) is a major cause of morbidity and mortality but it is usually underdiagnosed and undertreated. Patients with PAD present dysregulated procoagulant, anticoagulant, and fibrinolytic pathways leading to arterial and venous thrombosis. The risk of several ischemic-related complications could be mitigated with appropriate antithrombotic therapy, which plays a central role in all types of PAD. For years, antiplatelets have been indicated in patients with symptomatic PAD or those who have undergone revascularization. Unfortunately, a non-negligible proportion of patients with PAD will suffer from adverse events during the follow-up, even despite proper medical therapies for the prevention of PAD complications. Thus, there is room for improving clinical outcomes in these patients. Given the implication of both, primary and secondary hemostasis in arterial thrombosis and the pathophysiology of PAD, the combination of antiplatelets and anticoagulants has emerged as a potential antithrombotic alternative to antiplatelets alone. In this narrative review article, we have highlighted the most recent evidence about antithrombotic therapy in PAD patients, with a special focus on oral anticoagulation. Certainly, COMPASS and VOYAGER PAD trials have shown promising results. Thus, rivaroxaban in combination with aspirin seem to reduce cardiovascular outcomes with a similar bleeding risk compared to aspirin alone. Nevertheless, results from real-world studies are needed to confirm these observations, and other trials will provide novel evidence about the safety and efficacy of emerging anticoagulant agents.